Live Breaking News & Updates on Protease Medicines

Published: May 06, 2021
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) Catalyst Biosciences, Inc.. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 and provided a corporate update.
“We made significant progress across our Protease Medicines platform, specifically in our complement and hemostasis programs. We are preparing to initiate an observational trial in patients who have diseases related to CFI deficiency in mid-year 2021 to support our SQ enhanced CFI development candidate CB 4332 that will enter the clinic in 2022,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “In hemostasis, we dosed our first subject in the Crimson 1 Phase 3 registrational study of MarzAA, our next generation SQ FVIIa, in hemophilia A or B with inhibitors and are enrolling patients in a Phase 1/2 trial in other rare bleeding disorders.” ....

United States , Viia Fviia , Nassim Usman , Glanzmann Thrombasthenia , Systemic Complement Program , Company Phase , Catalyst Biosciences Inc , Gene Therapy Program , Journal Of American Society Hematology , Company Annual Report On Form , Exchange Commission , Degrader Program , Protease Medicines , American Society , Hemophiliab Using , Novel Factor , Higher Potency , Complement Program , Safety Monitoring Board , Catalyst Biosciences , Annual Report , Consolidated Statements , Months Ended March , ஒன்றுபட்டது மாநிலங்களில் , ந்யாஸைம் உஸ்மேன் , நிறுவனம் கட்டம் ,